ArticleFrontiers in cell and developmental biology2025
FLAIR-based radiomics signature from brain-tumor interface for early prediction of response to EGFR-TKI therapy in NSCLC patients with brain metastasis.
Article in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Evaluating response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) is crucial in non-small cell lung cancer (NSCLC) patients with brain metastases (BM). To explore values of multi-sequence MRI in early assessing response to EGFR-TKIs in non-small cell lung cancer (NSCLC) patients with BM. Approach: A primary cohort of 133 patients (January 2018 to March 2024) from center one and an external cohort of 52 patients (May 2017 to December 2022) from center two were established. Radiomics features were extracted from 4 mm brain-tumor interface (BTI) and whole BM region across T1-weighted contrast enhanced (T1CE) and T2-weighted (T2W) and T2 fluid-attenuated inversion recovery (T2-FLAIR) MRI sequences. The most relevant features were selected using the U test and least absolute shrinkage and selection operator (LASSO) method to develop the multi-sequence models based on BTI (RS-BTI-COM) and BM (RS-BM-COM). By integrating RS-BTI-COM with peritumoral edema volume (VPE), the combined model was built using logistic regression. Model performance was evaluated using the area under the ROC curve (AUC), sensitivity (SEN), specificity (SPE) and accuracy (ACC). Main Results: The constructed RS-BTI-COM demonstrated a higher association with early response to EGFR-TKI therapy than RS-BM-COM. The combined RS-BTIplusVPE, incorporating BTI-based radiomics features and VPE, exhibited the highest AUCs (0.843-0.938), SPE (0.808-0.905) and ACC (0.712-0.875) in the training, internal validation, and external validation cohort, respectively. Significance: The study developed a validated non-invasive model (RS-BTIplusVPE) based on integrating BTI-based radiomics features and VPE, which showed improved prediction of EGFR-TKI response in NSCLC patients with BM compared to tumor-focused models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.